Program Description:
Non–small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with ROS1 rearrangements identifying a small but critical subset of patients. These patients are often younger and non-smokers and face a high risk of central nervous system (CNS) involvement. While the therapeutic landscape has expanded to include multiple generations of tyrosine kinase inhibitors (TKIs), the emergence of complex resistance mechanisms poses a significant challenge to long-term disease control. This session is designed to equip oncology pharmacists with the advanced clinical and operational expertise required to navigate the evolving treatment landscape in ROS1-rearranged NSCLC. Because ROS1 fusions are often mutually exclusive with other oncogenic drivers, comprehensive biomarker testing via next-generation sequencing (NGS) has become an important first step to ensure these alterations are addressed through appropriate treatment selection and prevents the use of less effective, non-targeted therapies. Oncology pharmacists will explore the mechanistic differentiation of first- and next-generation TKI agents while exploring the clinical implications of investigational therapies. By synthesizing evidence from pivotal trials, this session provides a framework for interpreting NGS sequencing data, selecting initial therapy based on CNS burden, and strategically sequencing agents upon progression. Speakers will emphasize the pharmacist's role in institutional leadership from embedding retesting triggers into workflows to proactively managing unique toxicity profiles to optimize patient adherence and outcomes.
Target audience: Oncology Pharmacist
Type of activity: Application
Release date: June 18, 2026
Expiration date: August 18, 2026
Time to complete activity: 1.0 hour
Learner level: Intermediate, Advanced
Fee: Free
Educational
Objectives:
At the completion of this activity, participants will be able to:
- Utilize molecular and resistance testing results to guide evidence-based ROS1-directed treatment planning across lines of therapy
- Apply clinical trial data, CNS activity, and resistance mutation profiles to inform selection and sequencing of ROS1-targeted therapies
- Operationalize mechanism-based toxicity monitoring and management plans for ROS1-targeted therapies to maintain adherence and optimize long-term outcomes